Area of research
Physiology · Pulmonary and Respiratory Medicine
Research interest
Research focused on Benralizumab and Sarcoidosis, with related work in Mepolizumab, Asthma, Placebo. Notable publications include 'Transcriptional Blood Signatures Distinguish Pulmonary Tuberculosis, Pulmonary Sarcoidosis, Pneumonias and Lung Cancers', 'Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial', and 'Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study'.
Switching to twice-yearly depemokimab from mepolizumab/benralizumab in severe asthma: A multicenter, randomized, double-blind, Phase 3A Clinical Trial (NIMBLE)
Efficacy of mepolizumab in patients with COPD & type 2 inflammation: Pooled Phase III trial results
Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study
Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study
Burden of Uncontrolled Severe Asthma With and Without Elevated Type-2 Inflammatory Biomarkers
Cluster Analyses From the Real-World NOVELTY Study: Six Clusters Across the Asthma-COPD Spectrum
Efficacy and Safety of Masitinib in Corticosteroid-Dependent Severe Asthma: A Randomized Placebo-Controlled Trial
Pathogenic Mechanisms of Secondary Organic Aerosols
Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics
Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme
Nanocapsules containing Saussurea lappa essential oil: Formulation, characterization, antidiabetic, anti-cholinesterase and anti-inflammatory potentials
Chest CT for rapid triage of patients in multiple emergency departments during COVID-19 epidemic: experience report from a large French university hospital
How can we minimise the use of regular oral corticosteroids in asthma?
Lung function in Birt-Hogg-Dubé syndrome: a retrospective analysis of 96 patients
The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma
Exome sequencing and pathogenicity-network analysis of five French families implicate mTOR signalling and autophagy in familial sarcoidosis
Asthma patients’ perception on their care pathway: a qualitative study
Acute Respiratory Failure in Obesity-Hypoventilation Syndrome Managed in the ICU
Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial
Xolair-induced recurrent anaphylaxis through sensitization to the excipient polysorbate
Neutrophil elastase cleaves epithelial cadherin in acutely injured lung epithelium
Frequency of comorbidities in chronic obstructive pulmonary disease, and impact on all-cause mortality: A population-based cohort study
Familial vs. sporadic sarcoidosis: BTNL2 polymorphisms, clinical presentations, and outcomes in a French cohort
Long-Term Inhaled Corticosteroid Adherence in Asthma Patients with Short-Term Adherence
Prescribed therapy for asthma: therapeutic ratios and outcomes
Transcriptional Blood Signatures Distinguish Pulmonary Tuberculosis, Pulmonary Sarcoidosis, Pneumonias and Lung Cancers
Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study
Correction: Transcriptional Blood Signatures Distinguish Pulmonary Tuberculosis, Pulmonary Sarcoidosis, Pneumonias and Lung Cancers
Sarcoidosis complicating anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody biotherapy